Reassessment of CD62L as a marker of pre-effector T cells in the tumor draining lymph nodes of head and neck cancer patients

Otolaryngol Head Neck Surg. 2002 Feb;126(2):180-7. doi: 10.1067/mhn.2002.122263.

Abstract

Objectives: CD62L was evaluated as a determinant of human pre-effector T cells.

Study design and setting: Phenotype and cytokine secretion profiles of CD62L cells were determined based on activation status.

Results: CD62L(Low) T cells demonstrated significantly higher secretion of interleukin (IL)-10 and interferon (IFN)-gamma than did CD62L(High) T cells. After activation, the majority of cells expressed high levels of the CD62L surface marker. Postactivation levels of IL-10 production remained elevated or unchanged. In a murine B16 melanoma model, freshly isolated CD62L(Low) tumor draining lymph nodes (TDLN) T cells showed increased secretion of IL-2 and IL-4 but not of IL-10 or IFN-gamma. The surface expression of CD62L and cytokine secretion patterns were maintained after activation with concomitant increases in IL-10.

Conclusion: Our results provide evidence that CD62L(Low) T cells in TDLNs of progressively growing squamous cell carcinoma of the head and neck differ phenotypically and functionally from those of mouse origin.

Significance: Characterization of this human CD62L(Low) T cell population provides initial insight regarding novel surface markers in TDLN T cells that might correlate with antitumor reactivity.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Carcinoma, Squamous Cell / immunology*
  • Female
  • Flow Cytometry
  • Head and Neck Neoplasms / immunology*
  • Interleukins / immunology
  • L-Selectin / immunology*
  • Lymphocyte Activation
  • Melanoma, Experimental / immunology*
  • Mice
  • Phenotype
  • T-Lymphocytes, Regulatory / immunology*
  • Tumor Cells, Cultured

Substances

  • Interleukins
  • L-Selectin